Neal Ready - Concepedia

Author

Neal Ready

Also Known As

Billy W. Loo, Kelsey, Chris, N Ready, N. E. Ready, N. Ready, N.E. Ready, Nathan Gee, Neal E Ready, Neal E. Ready, Neal Edward Ready

305

Publications

32.3K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Bristol-Myers Squibb (United States)Memorial Sloan Kettering Cancer Center Duke University Sarah Cannon

About

Neal Ready is an author at Duke Medical Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	70	4.6K
2	Health Sciences	18	23	1.3K
3	Biostatistics	2	2	60
4	Cell Biology	2	2	47
5	Public Health	1	1	41

Neal Ready

114

Publications

28.7K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei, L. Paz-Ares, Leora Horn, New England Journal of Medicine	2015	9.3K
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie R. Brahmer, Karen L. Reckamp, Paul Baas, New England Journal of Medicine	2015	8.4K
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, The Lancet Oncology Multicohort StudyCheckmate 012MedicinePharmacologyImmune Checkpoint Inhibitor	2016	945
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Leora Horn, David R. Spigel, Everett E. Vokes, Journal of Clinical Oncology	2017	857
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Journal of Clinical Oncology	2021	614
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers Neal Ready, Matthew D. Hellmann, Mark M. Awad, Journal of Clinical Oncology	2019	584
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, The Lancet Oncology Dll3-targeted Antibody-drug ConjugateMedicineImmunologyImmune Checkpoint InhibitorCancer Treatment	2016	537
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Scott Gettinger, Naiyer A. Rizvi, Laura Q.M. Chow, Journal of Clinical Oncology	2016	493
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases E.E. Vokes, Neal Ready, Enriqueta Felip, Annals of Oncology	2018	462
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 Neal Ready, Anna F. Farago, Filippo de Braud, Journal of Thoracic Oncology	2018	373

Page 1